SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Furosemide Injection (Hospira, Inc.)

Trade Name: Not established
Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical active

Details of the Supplier of the Safety Data Sheet
Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture
GHS - Classification
Reproductive Toxicity: Category 2

Label Elements

Signal Word: Warning
Hazard Statements: H361d - Suspected of damaging the unborn child

Precautionary Statements:
P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations
Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furosemide</td>
<td>54-31-9</td>
<td>200-203-6</td>
<td>Repr. 2 (H361d)</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Acute Tox 5 (H303)</td>
<td></td>
</tr>
<tr>
<td>HYDROCHLORIC ACID</td>
<td>7647-01-0</td>
<td>231-595-7</td>
<td>Skin Corr.1B (H314)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>STOT SE 3 (H335)</td>
<td></td>
</tr>
<tr>
<td>SODIUM HYDROXIDE</td>
<td>1310-73-2</td>
<td>215-185-5</td>
<td>Skin Corr. 1A (H314)</td>
<td>**</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water for Injection</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

**Additional Information:**

* Proprietary
** to adjust pH

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

**Description of First Aid Measures**

**Eye Contact:**
Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:**
Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:**
Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:**
Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed
5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture
Hazardous Combustion Products: May include oxides of nitrogen and sulfur and products of chlorine

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters
During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
Measures for Cleaning / Collecting:
Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills:
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Furosemide
Pfizer OEL TWA-8 Hr: 40µg/m³
### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**HYDROCHLORIC ACID**

<table>
<thead>
<tr>
<th>Country</th>
<th>OEL - MAKs</th>
<th>Value 1</th>
<th>Value 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>5 ppm</td>
<td>8 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Belgium</td>
<td>5 ppm</td>
<td>8 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Bulgaria</td>
<td>5 ppm</td>
<td>8.0 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Cyprus</td>
<td>5 ppm</td>
<td>8 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Czech Republic</td>
<td>8 mg/m³</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estonia</td>
<td>5 ppm</td>
<td>8 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Germany - TRGS 900</td>
<td>2 ppm</td>
<td>3 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Germany (DFG)</td>
<td>2 ppm</td>
<td>3.0 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Greece</td>
<td>5 ppm</td>
<td>7 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Hungary</td>
<td>8 mg/m³</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ireland</td>
<td>5 ppm</td>
<td>8 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>5 ppm</td>
<td>8 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Japan - OELs</td>
<td>2 ppm</td>
<td>3.0 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Latvia</td>
<td>5 ppm</td>
<td>8 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Lithuania</td>
<td>5 ppm</td>
<td>8 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Luxembourg</td>
<td>5 ppm</td>
<td>8 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Malta</td>
<td>5 ppm</td>
<td>8 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Netherlands</td>
<td>8 mg/m³</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td>5 mg/m³</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Portugal</td>
<td>5 ppm</td>
<td>8 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Romania</td>
<td>5 ppm</td>
<td>8 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Slovakia</td>
<td>5 ppm</td>
<td>8.0 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Slovenia</td>
<td>5 ppm</td>
<td>8 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>5 ppm</td>
<td>7.6 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Switzerland</td>
<td>2 ppm</td>
<td>3.0 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Vietnam</td>
<td>5 mg/m³</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SODIUM HYDROXIDE**
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solution
Odor: No data available.
Molecular Formula: Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: 9.0 (8.0-9.3)
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.

Color: No data available.
Odor Threshold: No data available.
Molecular Weight: Mixture
9. PHYSICAL AND CHEMICAL PROPERTIES

Partition Coefficient: (Method, pH, Endpoint, Value)
Furosemide
No data available
SODIUM HYDROXIDE
No data available
HYDROCHLORIC ACID
No data available
Water for Injection
No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:
- Autoignition Temperature (Solid) (°C): No data available
- Flammability (Solids): No data available
- Flash Point (Liquid) (°C): No data available
- Upper Explosive Limits (Liquid) (% by Vol.): No data available
- Lower Explosive Limits (Liquid) (% by Vol.): No data available
Polymerization: No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable at normal conditions
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
Short Term: Ingestion may cause lowering of blood pressure. Accidental or incidental ingestion of large amounts may cause nausea, abdominal discomfort, headache or dizziness. Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions.

Acute Toxicity: (Species, Route, End Point, Dose)
Furosemide
- Rat Oral LD 50 2600 mg/kg
- Mouse Sub-tenon injection (eye) Minimum Symptomatic Dose 400mg/kg

HYDROCHLORIC ACID
- Rat Oral LD 50 238-277 mg/kg
11. TOXICOLOGICAL INFORMATION

Repeted Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

**Furosemide**
- 13 Week(s) Rat Oral 300 mg/kg LOAEL
- 13 Week(s) Mouse Oral 600 mg/kg LOAEL
- 6 Month(s) Dog Oral 10 mg/kg/day LOAEL
- 2 Year(s) Rat Oral 30 mg/kg/day LOAEL

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

**Furosemide**
- Reproductive & Fertility Rat Oral 2.9 mg/kg/day LOAEL Fertility
- Embryo / Fetal Development Rabbit Oral 25 mg/kg LOAEL Maternal Toxicity, Fetotoxicity
- Embryo / Fetal Development Rat Oral 12.5 mg/kg/day LOAEL Teratogenic
- Embryo / Fetal Development Mouse Oral 1250 mg/kg/day LOAEL Fetotoxicity, Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

**Furosemide**
- Bacterial Mutagenicity (Ames) Negative
- *In Vitro* Micronucleus Human Lymphocytes Positive
- Mammalian Cell Mutagenicity Mouse Lymphoma Positive

**HYDROCHLORIC ACID**
- Bacterial Mutagenicity (Ames) *Salmonella* Negative
- *In Vivo* Micronucleus Rat Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

**Furosemide**
- 2 Year(s) Male Rat Oral 15 mg/kg/day LOEL Tumors
- 104 Month(s) Female Mouse Oral 17.5 mg/kg LOEL Tumors
- 2 Year(s) Female Rat Oral, in feed 700 ppm NOEL Not carcinogenic
- 104 Month(s) Male Mouse Oral, in feed 1400 ppm NOEL Not carcinogenic

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

**Furosemide**
- IARC: Group 3 (Not Classifiable)

**HYDROCHLORIC ACID**
- IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

**Toxicity:** No data available
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

This material is not regulated for transportation / carriage.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Furosemide

- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Australia (AICS): Present
- Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
- EU EINECS/ELINCS List: 200-203-6

HYDROCHLORIC ACID

- CERCLA/SARA 313 Emission reporting: 1.0 %
- CERCLA/SARA Hazardous Substances and their Reportable Quantities: 5000 lb and 2270 kg
- CERCLA/SARA - Section 302 Extremely Hazardous TPQs: 500 lb
15. REGULATORY INFORMATION

| CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs | 5000 lb |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| Standard for the Uniform Scheduling for Drugs and Poisons: | Schedule 5 |
| EU EINECS/ELINCS List | 231-595-7 |

Water for Injection

| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| REACH - Annex IV - Exemptions from the obligations of Register: | Present |
| EU EINECS/ELINCS List | 231-791-2 |

SODIUM HYDROXIDE

| CERCLA/SARA 313 Emission reporting | Not Listed |
| CERCLA/SARA Hazardous Substances and their Reportable Quantities: | 1000 lb |
| and their Reportable Quantities: | 454 kg |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| Standard for the Uniform Scheduling for Drugs and Poisons: | Schedule 5 |
| EU EINECS/ELINCS List | 215-185-5 |

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child
Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage
Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 12 - Ecological Information.

Revision date: 14-Aug-2018


Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet